Pfenex And Alvogen Suffer Teriparatide Setback
FDA Asks For More Data Before It Can Grant Equivalence
Pfenex and partner Alvogen have suffered a setback on their PF708 teriparatide in the US, after the country’s Food and Drug Administration asked for more information to support a long-awaited designation of therapeutic equivalence to the Forteo brand.
